Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 29;10(28):16727-16731.
doi: 10.1039/d0ra03291c. eCollection 2020 Apr 23.

Induction of ADCC by a folic acid-mAb conjugate prepared by tryptophan-selective reaction toward folate-receptor-positive cancer cells

Affiliations

Induction of ADCC by a folic acid-mAb conjugate prepared by tryptophan-selective reaction toward folate-receptor-positive cancer cells

Hiroshi Tagawa et al. RSC Adv. .

Abstract

We developed conjugates between monoclonal antibody (mAb) and folic acid (FA) by using a tryptophan (Trp)-selective reaction, which yields relatively homogenous products compared to conventional methods. The obtained mAb-FA conjugates showed significant cellular cytotoxicity toward folate receptor-expressing cancer cells, demonstrating that the conjugates retained the Fc region's original function.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts to declare.

Figures

Fig. 1
Fig. 1. Crystal structures of the Fc region of IgG1 with Trp residues shown in red. Each chain is shown in green and light green colors. Recognition residues of the three proteins are shown in different colors: magenta (FcγRIIIa, CD16a), cyan (C1q), blue (overlapped residues of FcγRIIIa and C1q), and orange (FcRn). PDB ID: 1E4K.
Fig. 2
Fig. 2. The structures of the mAb–FA conjugates via Trp reside (A) and schematic illustration of ADCC induction by the mAb–FA conjugates which bind to the FR-α on a cancer cell via FA (B).
Fig. 3
Fig. 3. Preparation of the mAb–FA conjugates.
Fig. 4
Fig. 4. mAb–FA binds to the FR-α expressed on IGROV-1 cells. (A) IGROV-1 cells were incubated with anti-CD20–FA conjugates with different linker lengths (PEG, n = 4, 8, 12). After a washing step, FITC-labelled anti-IgG Fc polyclonal antibody was added to each sample, and the median of fluorescent intensity (FI) was measured using flow cytometry. (n = 3, mean ± SEM.) (B) IGROV-1 cells were seeded and incubated overnight. mAb, mAb–FA, or mAb–FA + excess FA were added. After washing, mAb–FA bound to the cells was detected using anti-IgG-Fc polyclonal IgG. Cells were also stained with Hoechst 33342. (C) IGROV-1 cells were treated with increasing concentrations of mAb–FA, and the antibodies bound to the cells were quantified. (n = 3, mean ± SEM.)
Fig. 5
Fig. 5. mAb–FA induces ADCC against FR-α+ IGROV-1 cells. (A) IGROV-1 cells were treated with mAb (10 nM), mAb–FA (10 nM), or mAb–FA (10 nM) + FA (1 μM) and co-cultured with KHYG-1/CD16a-158V for 16 h. Cellular cytotoxicity was quantified by an LDH assay (n = 3, mean ± SEM). A statistically significant difference between “mAb–FA” and the others was observed at all effector/target ratios. (B) After co-culturing, culture supernatants were collected for detection of IFN-γ by ELISA (E/T = 4, n = 3, mean ± SEM). Statistical analyses were carried out using two-tailed Student's t-test or Welche's t-test depending on the result of F-test. **p < 0.01, ***p < 0.005.

References

    1. de Taeye S. W. Rispens T. Vidarsson G. The Ligands for Human IgG and Their Effector Functions. Antibodies. 2019;8:30. doi: 10.3390/antib8020030. - DOI - PMC - PubMed
    1. Wang W. Erbe A. K. Hank J. A. Morris Z. S. Sondel P. M. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front. Immunol. 2015;6:368. - PMC - PubMed
    1. Idusogie E. E. Presta L. G. Gazzano-Santoro H. Totpal K. Wong P. Y. Ultsch M. Meng Y. G. Mulkerrin M. G. Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc. J. Immunol. 2000;164:4178–4184. doi: 10.4049/jimmunol.164.8.4178. - DOI - PubMed
    1. Kuo T. T. Baker K. Yoshida M. Qiao S. W. Aveson V. G. Lencer W. I. Blumberg R. S. Neonatal Fc receptor: from immunity to therapeutics. J. Clin. Immunol. 2010;30:777–789. doi: 10.1007/s10875-010-9468-4. - DOI - PMC - PubMed
    1. Alley S. C. Okeley N. M. Senter P. D. Antibody-drug conjugates: targeted drug delivery for cancer. Curr. Opin. Chem. Biol. 2010;14:529–537. doi: 10.1016/j.cbpa.2010.06.170. - DOI - PubMed